PMN News & Events

Promis Neurosciences Inc trading halted, volatility trading pause

ProMIS Neurosciences announced completion of enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial, evaluating PMN310, the Company's lead therapeutic antibody candidate for the treatment of AD. The Company remains on track to conduct a blinded 6-month interim analysis in Q2 2026, including an evaluation of key plasma and cerebrospinal fluid biomarkers, followed by final unblinded 12-month top-line analysis expected in Q4 2026.

ProMIS Neurosciences announced a publication in the peer-reviewed journal Alzheimer's & Dementia: Translational Research & Clinical Interventions. entitled, "Relationship between efficacy and preferential targeting of soluble Abeta aggregates." Key Findings and Implications for PMN310: PMN310 showed the highest resistance to monomer competition among all antibodies tested, preserving oligomer binding while pan-Abeta antibodies lost activity in in vitro models. This suggests that a higher proportion of each dose of PMN310 could be available to reach the relevant toxic targets, which could potentially translate into clinical benefit in patients. Findings provide preclinical evidence supporting a possible reduced ARIA risk. All other antibodies tested in the study appeared to bind monomers and/or plaque to varying degrees. PMN310 was the only antibody in the study showing strict specificity for toxic soluble oligomers while avoiding monomers and plaque.